SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-378986"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-378986" > Drug sensitivity te...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005004naa a2200553 4500
001oai:DiVA.org:uu-378986
003SwePub
008190319s2019 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:140324082
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3789862 URI
0247 a https://doi.org/10.1038/s41416-018-0359-42 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1403240822 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Brodin, Bertha A.u Karolinska Institutet4 aut
2451 0a Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas
264 c 2019-02-12
264 1b Springer Science and Business Media LLC,c 2019
338 a print2 rdacarrier
520 a BACKGROUND: Heterogeneity and low incidence comprise the biggest challenge in sarcoma diagnosis and treatment. Chemotherapy, although efficient for some sarcoma subtypes, generally results in poor clinical responses and is mostly recommended for advanced disease. Specific genomic aberrations have been identified in some sarcoma subtypes but few of them can be targeted with approved drugs. METHODS: We cultured and characterised patient-derived sarcoma cells and evaluated their sensitivity to 525 anti-cancer agents including both approved and non-approved drugs. In total, 14 sarcomas and 5 healthy mesenchymal primary cell cultures were studied. The sarcoma biopsies and derived cells were characterised by gene panel sequencing, cancer driver gene expression and by detecting specific fusion oncoproteins in situ in sarcomas with translocations. RESULTS: Soft tissue sarcoma cultures were established from patient biopsies with a success rate of 58%. The genomic profile and drug sensitivity testing on these samples helped to identify targeted inhibitors active on sarcomas. The cSrc inhibitor Dasatinib was identified as an active drug in sarcomas carrying chromosomal translocations. The drug sensitivity of the patient sarcoma cells ex vivo correlated with the response to the former treatment of the patient. CONCLUSIONS: Our results show that patient-derived sarcoma cells cultured in vitro are relevant and practical models for genotypic and phenotypic screens aiming to identify efficient drugs to treat sarcoma patients with poor treatment options.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
7001 a Wennerberg, Kristeru Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; Univ Copenhagen, BRIC, Copenhagen, Denmark4 aut
7001 a Lidbrink, Elisabetu Karolinska Univ Hosp, Dept Breast Canc Endocrine Tumors & Sarcoma, Stockholm, Sweden4 aut
7001 a Brosjö, Otteu Karolinska Institutet4 aut
7001 a Potdar, Swapnilu Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland4 aut
7001 a Wilson, Jennifer N.u Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut
7001 a Ma, Liminu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut
7001 a Moens, Lotteu Uppsala universitet,Klinisk och experimentell patologi4 aut0 (Swepub:uu)lotmo617
7001 a Hesla, Asleu Karolinska Institutet4 aut
7001 a Porovic, Edvinu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut
7001 a Bernhardsson, Edvinu Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Stockholm, Sweden4 aut
7001 a Papakonstantinou, Antroulau Karolinska Institutet4 aut
7001 a Bauer, Henriku Karolinska Institutet4 aut
7001 a Tsagkozis, Panagiotisu Karolinska Institutet4 aut
7001 a von Sivers, Karinu Karolinska Univ Hosp, Dept Radiol, Stockholm, Sweden4 aut
7001 a Wejde, Johanu Karolinska Univ Hosp, Dept Cytol & Pathol, Stockholm, Sweden4 aut
7001 a Ostling, Paiviu Karolinska Institutet4 aut
7001 a Kallioniemi, Olliu Karolinska Institutet4 aut
7001 a Stragliotto, Christina Linderu Karolinska Univ Hosp, Dept Breast Canc Endocrine Tumors & Sarcoma, Stockholm, Sweden4 aut
7102 a Karolinska Institutetb Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; Univ Copenhagen, BRIC, Copenhagen, Denmark4 org
7730 t British Journal of Cancerd : Springer Science and Business Media LLCg 120:4, s. 435-443q 120:4<435-443x 0007-0920x 1532-1827
8564 u https://www.nature.com/articles/s41416-018-0359-4.pdf
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-378986
8564 8u https://doi.org/10.1038/s41416-018-0359-4
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:140324082

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy